Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christine E Staatz

Showing results (11-20 of 100) with videos related to

Pageof 10
Sort By:
Therapeutic Drug Monitoring|January 1, 2014
Effects of combinational CYP3A5 6986A>G polymorphism in graft liver and native intestine on the pharmacokinetics of tacrolimus in liver transplant patients: a meta-analysisJefferson A Buendia, Guillermo Bramuglia, Christine E Staatz
British Journal of Clinical Pharmacology|January 26, 2006
Population pharmacokinetic modelling of gentamicin and vancomycin in patients with unstable renal function following cardiothoracic surgeryChristine E Staatz, Colette Byrne, Alison H Thomson
Pharmacoepidemiology and Drug Safety|March 4, 2009
A comparison of mycophenolate use in Australia and Northern Europe, and the impact on the pharmaceutical benefits schemeChristine E Staatz, Alesha J Smith, Susan E Tett
Clinical Pharmacokinetics|February 23, 2010
Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part IChristine E Staatz, Lucy K Goodman, Susan E Tett
Drugs in R&D|November 15, 2018
Is Conversion from Mycophenolate Mofetil to Enteric-Coated Mycophenolate Sodium Justifiable for Gastrointestinal Quality of Life?Kyle M Gardiner, Susan E Tett, Christine E Staatz
Transplantation|May 14, 2010
Evaluation of the mycophenolic acid exposure estimation methods used in the APOMYGERE, FDCC, and Opticept trialsKatherine A Barraclough, Nicole M Isbel, Christine E Staatz
Pharmacogenomics|March 19, 2010
Pharmacogenetic influences on mycophenolate therapyKatherine A Barraclough, Katie J Lee, Christine E Staatz
Annals of Transplantation|January 6, 2016
Multinational Evaluation of Mycophenolic Acid, Tacrolimus, Cyclosporin, Sirolimus, and Everolimus UtilizationKyle M Gardiner, Susan E Tett, Christine E Staatz
Antimicrobial Agents and Chemotherapy|March 23, 2016
Assessing Predictive Performance of Published Population Pharmacokinetic Models of Intravenous Tobramycin in Pediatric PatientsCeleste Bloomfield, Christine E Staatz, Sean Unwin, et al.
Clinical Pharmacokinetics|March 11, 2010
Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part IIChristine E Staatz, Lucy K Goodman, Susan E Tett
Pageof 10

Showing results (11-20 of 100) with videos related to

Sort By:
Pageof 10
Therapeutic Drug Monitoring|January 1, 2014
Effects of combinational CYP3A5 6986A>G polymorphism in graft liver and native intestine on the pharmacokinetics of tacrolimus in liver transplant patients: a meta-analysisJefferson A Buendia, Guillermo Bramuglia, Christine E Staatz
British Journal of Clinical Pharmacology|January 26, 2006
Population pharmacokinetic modelling of gentamicin and vancomycin in patients with unstable renal function following cardiothoracic surgeryChristine E Staatz, Colette Byrne, Alison H Thomson
Pharmacoepidemiology and Drug Safety|March 4, 2009
A comparison of mycophenolate use in Australia and Northern Europe, and the impact on the pharmaceutical benefits schemeChristine E Staatz, Alesha J Smith, Susan E Tett
Clinical Pharmacokinetics|February 23, 2010
Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part IChristine E Staatz, Lucy K Goodman, Susan E Tett
Drugs in R&D|November 15, 2018
Is Conversion from Mycophenolate Mofetil to Enteric-Coated Mycophenolate Sodium Justifiable for Gastrointestinal Quality of Life?Kyle M Gardiner, Susan E Tett, Christine E Staatz
Transplantation|May 14, 2010
Evaluation of the mycophenolic acid exposure estimation methods used in the APOMYGERE, FDCC, and Opticept trialsKatherine A Barraclough, Nicole M Isbel, Christine E Staatz
Pharmacogenomics|March 19, 2010
Pharmacogenetic influences on mycophenolate therapyKatherine A Barraclough, Katie J Lee, Christine E Staatz
Annals of Transplantation|January 6, 2016
Multinational Evaluation of Mycophenolic Acid, Tacrolimus, Cyclosporin, Sirolimus, and Everolimus UtilizationKyle M Gardiner, Susan E Tett, Christine E Staatz
Antimicrobial Agents and Chemotherapy|March 23, 2016
Assessing Predictive Performance of Published Population Pharmacokinetic Models of Intravenous Tobramycin in Pediatric PatientsCeleste Bloomfield, Christine E Staatz, Sean Unwin, et al.
Clinical Pharmacokinetics|March 11, 2010
Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part IIChristine E Staatz, Lucy K Goodman, Susan E Tett
Pageof 10